StockData

Chemomab Therapeutics vs Rein Therapeutics

CMMB and RNTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CMMB and RNTX compare

Rein Therapeutics scores higher on the StockData Score (6 against 5 for Chemomab Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCMMBRNTX
Size and price
Market cap–$34.5M
Share price$1.62$0.400
Change, 1 year−36.5%−70.4%
Change, 5 years−95.4%−97.0%
Beta (5Y)2.082.18
Employees1010
StockData Score
Total score56 (better)
Valuation score01 (better)
Growth score00
Performance score00
Health score55
Dividend score00
Valuation
P/B–0.6×
Growth
EPS growth (TTM)−53.8%–
EPS growth, 5Y average−16.4%–
Profitability
Return on equity−97.9%−96.4% (better)
Return on invested capital−8103%−145% (better)
Financial health
Debt / equity0.000.00
Current ratio6.41 (better)4.27
Altman Z-score–−8.75
Piotroski F-score3 (better)2
Dividends and buybacks
Dividend yield–0.00%
Years of dividend growth–0
Buyback yield–−159%
Shareholder yield–−159%
Ownership
Held by institutions0.07%47.3%
Held by insiders27.4%9.6%
Insider net buying, 12 months$13.7K$74.7K (better)
Short interest, % of float–0.91%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.